Skip To Main Content
Jacob Orme on Muck Rack

Jacob Orme

As seen in: JAMA (The Journal of the American Medical Association), Journal of Clinical Oncology, Journal of Nuclear Medicine, UroToday, University Chronicle

Get in touch with Jacob

Contact Jacob, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Jacob Orme’s Biography

Read Full Bio →

Hallu Motion preț

Anchorman Malika is interested in new taking photographs, warhammer. She gets motivated by watching a Boston bruins icehockey-game inside the arena.

Nearly every single small new works

Articles

Strategic Isolation of a Putative COX Enzyme Honors Thesis

|
By Jacob Orme, Daniel Simmons, Brigham Young
| scholarsarchive.byu.edu
Keywords strategic isolation, putative COX enzyme, honors thesis College Physical and Mathematical Sciences Department Church History and Doctrine Abstract Most of the results of my work are confidential pending publication. This also applies to the public availability of my honors thesis, which will not be printed until later this year as a result.
Open in Who Shared Issue with article?

Neurologic Symptoms After 177Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center Experience

|
By Gokce Belge Bilgin, Brian J. Burkett, Cem Bilgin, Jacob Orme
| Journal of Nuclear Medicine Verified
Treatment with 177Lu-prostate-specific membrane antigen (PSMA)–617 (177Lu-vipivotide tetraxetan [Pluvicto]) prolongs both progression-free and overall survival in advanced PSMA-positive metastatic castration-resistant prostate cancer. Data examining specifically neurologic symptoms after 177Lu-PSMA-617 treatment are scarce. In this study, we aimed to review the neurologic findings in a large cohort of metastatic castration-resistant prostate cancer patients undergoing 177Lu-PSMA-617 therapy.
Open in Who Shared Issue with article?

Delaying Prostate-Specific Antigen Progression in Biochemically Recurrent Prostate Cancer: Is It Clinically Meaningful?

|
By Daniel Childs, Jacob Orme
| brnw.ch
Treating prostate cancer with intensified androgen blockade is widely accepted.
Open in Who Shared Issue with article?
See all 8 articles

Awards

Society of Environmental Journalists Award

View Award